Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, discusses a randomized trial assessing health-related quality of life in patients with 

-positive non—small cell lung cancer who were treated with brigatinib (Alunbrig) versus crizotinib (Xalkori).

The study, updated quality-of-life data of which were presented at the 2019 World Conferenc on Lung Cancer, demonstrated that brigatinib is favorable in these patients, including those with brain metastases. Overall, brigatinib was superior in improving health-related quality of life.

Videos

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Rosario Garcia Campelo, MD

Articles

Dr. Campelo on the Rationale for the ALTA-1L Trial